According to Tracxn, these are the notable deals this week across the sectors of artificial intelligence, cybersecurity, and big data analytics.
Click here to view past Deals of the Week.
- Iambic Therapeutics – AI-driven drug discovery platform for the treatment of cancer, raised a Series B – $100M round from Abingworth, ascenta, Sequoia Capital, Orbimed and others.
- Prins – Provider of an AI-driven digital training product, raised a Series B – $100M round from AAB Venture Capital.
- MicroSure – Provider of a robot systems for microsurgery, raised a Seed B – $ 39.8M round from European Union, BOM, Invest-NL, Innovation Industries and others.
- Osapiens – Provider of AI & SaaS-enabled supply chain augmentation solutions, raised a Series B – $26.2M round from Armira.
- Amperon – AI-driven IoT platform for energy retailers & utilities, raised a Series B – $20M round from Energize Capital, HSBC, D. E. Shaw Group, Orsted and others.
- BOLT – AI and SaaS-enabled platform offering comprehensive electric vehicle charging operator and management solutions, raised a Series B – $20M round from Union Square Ventures, Prime Venture Partners, ITI Growth Opportunities.
- Yubico – Provider of password less authentication solutions, raised a Series B – $204M round.
- Verisoul – AI based identity verification solution, raised a Series A – $3.8M round.
- Mitiga – Provider of IT security services, raised a Series A round from Cisco Investments.
Big Data Analytics
- Responsibly – Artificial intelligence based supplier data platform for the supply chain industry, raised a Seed – $2.4M round from Hambro Perks, PI LABS.
Robotics Process Automation
- Induced – AI-based RPA platform for basic automation, raised a Seed – $2.3M round from Sam Altman, Peak XV Partners, Balaji Srinivasan, Julian Weisser and others.
Photo: Tom Miller, CEO of Iambic, on the new funding: “With the Series B funding, we intend to advance multiple AI-discovered candidates into the clinic and expand our pipeline, demonstrating how the Iambic platform can deliver better therapeutics to patients in less time, with optimized target product profiles for greater likelihood of clinical success,” said (Photo credit: Iambic)